The legal action, spearheaded by the firm Faruqi & Faruqi, LLP, centers on claims that ARS Pharmaceuticals provided overly optimistic projections to the market while failing to disclose that CVS Caremark had deferred a decision on expanded insurance coverage for the company’s product, neffy, until January 2027. According to the complaint, these omissions artificially inflated the company's stock price.
The market reacted sharply on June 24, 2026, when ARS announced that no new formulary additions for neffy would occur in the July cycle. Following the disclosure, the company's share price dropped $2.52—a decline of nearly 24%—closing at $8.02 on June 25 amid high trading volume. Investors who held shares during the specified period may be eligible to participate in the recovery, regardless of whether they choose to serve as lead plaintiff. Those interested in the litigation or seeking to discuss their legal options are encouraged to contact partner Josh Wilson at 877-247-4292.
Comments (0)
No comments yet. Be the first!